Shl Telemedicine Ltd. · SIX:SHLTN
Shl Telemedicine — Investor Presentation (April 2024)
23 slides from Shl Telemedicine's investor presentation, Apr 17, 2024
Slide 1: SHL Telemedicine Yearly Investor Presentation 2023
SHL Telemedicine Yearly Investor Presentation 2023
Slide 2: Forward looking statements
2 מידע צופה פני עתיד Forward looking statements This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation,
Slide 3: SHL Telemedicine At a Glance
SHL Telemedicine At a Glance 3 Active in 2 Models: B2B & B2C Active in 3 Territories Over 30 years of experience and data aggregated $57.1M Revenues in 2023 Unique Portable, 12-lead ECG technology SmartHeart ® Platform Nasdaq: SHLT SWX: SHLTN Traded on NASDAQ and in Switzerland SHL is a leader in th
Slide 4: FY2023 Financial Data Overview
FY2023 Financial Data Overview 4 (*) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures (**) Constant curren
Slide 5: Operational Overview
Operational Overview Active in 3 Territories, B2B & B2C 5 Germany USA Israel SHL Telemedicine SHL B2C SHL B2B Chronic B2B Telehealth B2B SmartHeart B2B Sales SmartHeart B2C Sales Providing advanced medical services to large institutional customers in Israel, through Mediton Advanced B2C telemedicine
Slide 6: Looking Ahead 2024 Outlook
Looking Ahead 2024 Outlook 6 Israel Germany USA Accumulating meaningful operational data for optimizing sales strategy Significant advancements in major B2B sales channel Continued growth in Virtual Visits services Advancing operational efficiency towards break even, with the goal of achieving profi
Slide 7: Israel Activity
Israel Activity Advanced B2C Telemedicine Services Advanced B2B Medical Services
Slide 8: Israel Activity 2023 Results Summary
Israel Activity 2023 Results Summary 8 SHL Leads in B2C Telemedicine Advanced B2B Medical Services Selling cardiac monitoring services to the end customer: a 12-lead personal ECG device for remote medical data transfer, a 24/7 medical center, and intensive care mobility in coverage areas Over 100 in
Slide 9: Israeli Activity Key Annual Operating Data
Israeli Activity Key Annual Operating Data 800,000 Contacts with the telemedicine center 18,000 Tests performed at the medical centers Over 23,000 Ambulances Alerted 1,500,000 Online data transmissions from end user devices to the medical center 315,000 Contact with customer service center 33,000 Vi
Slide 10: B2C activity in Israel - strong & leading brand in telemedicine
10 B2C activity in Israel - strong & leading brand in the field of telemedicine services SHL operates a professional medical center for remote guidance and treatment around the clock offering advanced intensive care mobile units. 50,000Subscribers $40 Average per subscriber / month 6 years average p
Slide 11: Germany Activity
2 Germany Activity
Slide 12: SHL Germany Telemedicine Services
SHL Germany Telemedicine Services 12 Remote medicine services such as Virtual Visit and treatment of chronic patients, are becoming the Standard of Care The company has agreements with leading health insurers covering about 30% of the German health insurance market (about 25 million insured) SHL is
Slide 13: Germany Virtual Visits Service
13 Germany Virtual Visits Service Penetrating a market of about 800 million annual physical doctor visits The virtual visit service is already available to 12.4 million BARMER and AOK PLUS insureds throughout Germany Consistent Growth since Launch in April 2023 VIRTUAL VISITS (*) https://www.statist
Slide 14: USA Activity
USA Activity SHLUSA smartheart
Slide 15: USA B2C plan: focus on direct-to-consumer sales of SmartHeart ECG
USA 15 B2C plan: focus on direct-to-consumer sales of the SmartHeart® ECG Tier1 Strategic customers relationships strengthening our reputation in support of the SmartHeart® direct-to-consumer move Leveraging our network of cardiologists that is already set up across the US REVENUES FY23 $0.9M REVENU
Slide 16: USA strategy prioritizing direct-to-consumer sales of SmartHeart
USA Established a robust strategy in 2023 that prioritizes direct-to-consumer sales of SmartHeart® 16 “With a focus on remote cardiac care, SHL Telemedicine harnesses the power of digital tools to bring life-saving services directly to patients, regardless of their location.” Establishing Go To Mark
Slide 17: Mayo Clinic and Imperial College London study results
USA 17 Mayo Clinic HELP MI Telemedicine group compliant users vs. control group Imperial College London TELE-ACS Study Telemedicine group vs. control standard care group at 3 months follow-up Presented at ACC24 Late-Breaking Clinical Trial Sessions Accepted for publication in the Journal of the Amer
Slide 18: Financials
Financials Selected data from P&L statements, balance sheet and cash flow
Slide 19: Financials - P&L
Financials - P&L* 19 (*) compared to FY 2022 in constant currency, Please see Supplemental Information at end of presentation for a description of the basis of presentation of the constant currency amount calculations as required by the rules of the U.S. Securities Exchange Commission with respect t
Slide 20: Financials - Balance Sheet and Cashflow
Financials - Balance Sheet and Cashflow 20 Total cash and short-term investments In USD million In USD million FY 2023 FY 2022 Cash and cash equivalents 6.7 4.5 Short term investments 19.6 14.2 Total cash and short-term investments 26.3 18.7 Short term bank debt 2.2 2.2 Long term bank debt 10.5 13.0
Slide 21: Thanks SHL Telemedicine
Thanks SHL Telemedicine
Slide 22: Supplemental Information
22 Supplemental Information *Numbers are rounded up. **Adjusted EBIT: Please see the Adjusted EBITDA and Adjusted EBIT Table below. ***Adjusted EBITDA: Please see the Adjusted EBITDA and Adjusted EBIT Table below In the table below, FY 2022 results have been presented at FY 2023 exchange rates1. Man
Slide 23: Supplemental Information
23 Supplemental Information (1) Constant currency – to enable meaningful comparison between FY2023 and FY2022 results, FY2022 results are also presented at FY2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus t
SHL Telemedicine — Investor Presentation (April 2024) on 6ix